FasL blockade suppresses liver metastasis and prolongs survival in small-cell lung cancer

Small-cell lung cancer (SCLC) is an aggressive malignancy characterised by early metastatic dissemination, frequent relapse and poor long-term survival. Despite advances in immunotherapy, durable disease control remains challenging, highlighting the need to identify therapeutic vulnerabilities beyond conventional tumour-cell killing and immune checkpoint inhibition. Here, we uncover an unexpected contribution of Fas-Fas ligand (FasL) signalling to SCLC metastatic progression and demonstrate the therapeutic potential of targeting this pathway. Using an autochthonous Rb1/Trp53-deficient mouse model, we show that genetic Fas deletion markedly suppresses liver metastatic disease, identifying a previously unrecognised contribution of Fas signalling to metastatic progression. Notably, despite this antimetastatic effect, Fas deletion during tumour initiation did not improve survival and was accompanied by pronounced alterations in pulmonary tissue architecture. As these alterations may reflect adverse consequences of Fas deletion in non-malignant pulmonary populations, we reasoned that pharmacological FasL blockade in established disease could provide therapeutic benefit while circumventing the detrimental consequences for pulmonary tissue homeostasis associated with genetic Fas deletion. Remarkably, only six administrations of a soluble Fas-Fc fusion protein over three weeks significantly prolonged survival and substantially reduced the incidence and burden of liver metastases. FasL blockade was also associated with enhanced inflammatory and immune-response transcriptional signatures in the liver, while its combination with anti-PD-1 increased pulmonary immune-cell accumulation without conferring additional survival benefit. These data suggest that the biological consequences of targeting this pathway may depend on the timing and cellular context of intervention. Together, our findings identify Fas-FasL signalling as an unexpected regulator of SCLC metastatic progression and establish FasL blockade as a promising therapeutic strategy capable of prolonging survival in established disease beyond conventional immune checkpoint inhibition.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.09.765391
Primary Topic
Lung Cancer Research Studies
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

FasL blockade suppresses liver metastasis and prolongs survival in small-cell lung cancer

Julia Saggau, Filippo Beleggia, Antonella Montinaro, Eva Rieser et al.
bioRxiv (Cold Spring Harbor Laboratory)
Lung Cancer Research Studies
preprint

FasL blockade suppresses liver metastasis and prolongs survival in small-cell lung cancer

Julia Saggau, Filippo Beleggia, Antonella Montinaro, Eva Rieser, Britta Jenke, Gianmaria Liccardi, Alexandra Florin, Henning Walczak, Maria Cartolano, Debora Bonasera, Reinhard Buettner, Venelin Nikolov, Umut Akgül, H. Christian Reinhardt, Anne Berghaus
preprint en

Abstract

Small-cell lung cancer (SCLC) is an aggressive malignancy characterised by early metastatic dissemination, frequent relapse and poor long-term survival. Despite advances in immunotherapy, durable disease control remains challenging, highlighting the need to identify therapeutic vulnerabilities beyond conventional tumour-cell killing and immune checkpoint inhibition. Here, we uncover an unexpected contribution of Fas-Fas ligand (FasL) signalling to SCLC metastatic progression and demonstrate the therapeutic potential of targeting this pathway. Using an autochthonous Rb1/Trp53-deficient mouse model, we show that genetic Fas deletion markedly suppresses liver metastatic disease, identifying a previously unrecognised contribution of Fas signalling to metastatic progression. Notably, despite this antimetastatic effect, Fas deletion during tumour initiation did not improve survival and was accompanied by pronounced alterations in pulmonary tissue architecture. As these alterations may reflect adverse consequences of Fas deletion in non-malignant pulmonary populations, we reasoned that pharmacological FasL blockade in established disease could provide therapeutic benefit while circumventing the detrimental consequences for pulmonary tissue homeostasis associated with genetic Fas deletion. Remarkably, only six administrations of a soluble Fas-Fc fusion protein over three weeks significantly prolonged survival and substantially reduced the incidence and burden of liver metastases. FasL blockade was also associated with enhanced inflammatory and immune-response transcriptional signatures in the liver, while its combination with anti-PD-1 increased pulmonary immune-cell accumulation without conferring additional survival benefit. These data suggest that the biological consequences of targeting this pathway may depend on the timing and cellular context of intervention. Together, our findings identify Fas-FasL signalling as an unexpected regulator of SCLC metastatic progression and establish FasL blockade as a promising therapeutic strategy capable of prolonging survival in established disease beyond conventional immune checkpoint inhibition.

bioRxiv (Cold Spring Harbor Laboratory)
Translational Genomics Research Institute (US), University of Cologne (DE), Essen University Hospital (DE), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE), CRUK Lung Cancer Centre of Excellence (GB), University Hospital Cologne (DE), University College London (GB)
Alexander von Humboldt-Stiftung, Deutsche Forschungsgemeinschaft
Good health and well-being
Lung Cancer Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon